Short Interest in Briacell Therap (NASDAQ:BCTX) Expands By 174.9%

Briacell Therap (NASDAQ:BCTX) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totaling 281,381 shares, an increase of 174.9% from the December 15th total of 102,341 shares. Currently, 15.8% of the company’s shares are sold short. Based on an average daily volume of 74,326 shares, the days-to-cover ratio is currently 3.8 days. Based on an average daily volume of 74,326 shares, the days-to-cover ratio is currently 3.8 days. Currently, 15.8% of the company’s shares are sold short.

Briacell Therap Stock Performance

Shares of NASDAQ:BCTX opened at $10.92 on Wednesday. The business’s 50-day simple moving average is $9.14 and its 200 day simple moving average is $10.73. The company has a market cap of $20.53 million, a P/E ratio of -0.25 and a beta of 1.38. Briacell Therap has a one year low of $6.00 and a one year high of $98.20.

Briacell Therap (NASDAQ:BCTX) last issued its quarterly earnings data on Monday, December 15th. The company reported ($4.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($12.11) by $7.76. Analysts predict that Briacell Therap will post -2.45 earnings per share for the current year.

Institutional Investors Weigh In On Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC acquired a new position in Briacell Therap (NASDAQ:BCTX) during the third quarter, according to the company in its most recent filing with the SEC. The fund acquired 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned approximately 1.63% of Briacell Therap at the end of the most recent reporting period. Institutional investors own 15.42% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $320.00.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.